dulanermin

Dulanermin is a recombinant human soluble protein corresponding to amino acids 114–281 of the Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). It functions by specifically inducing apoptosis in cancer cells through binding to and activating proapoptotic death receptors DR4 (TRAIL receptor 1) and DR5 (TRAIL receptor 2), leading to the activation of apoptotic pathways. Dulanermin was developed as an antineoplastic agent, primarily for the treatment of various cancers including non-small cell lung cancer (NSCLC), colorectal cancer, and non-Hodgkin's lymphoma. The drug was originally developed by Amgen, with Genentech also involved in its development.

Other names

Apo2L/TRAILTNF-related apoptosis-inducing ligandHuman tumor necrosis factor ligand superfamily member 10